Sarcopenia in hemodialysis patients and blood ghrelin and leptin concentratio
Not Applicable
- Conditions
- Chronic renal failure
- Registration Number
- JPRN-UMIN000034616
- Lead Sponsor
- Saitama Tsukinomori Clinic
- Brief Summary
1. In 10 hemodialysis patients receiving cinacalcet, leptin was 0.67+0.09 (Log [leptin ng/mL]), active ghrelin was 1.22+0.13 (Log [active ghrelin fmol/mL]), and desacyl ghrelin was 2.15+0.18 (Log [desacyl ghrelin fmol/mL]). 2. In these patients, 8 weeks after changing from cinacalcet to evocalcet, leptin was 0.70+0.12 (Log [leptin ng/mL]) and active ghrelin was 1.37+0.11 (Log [active ghrelin fmol/mL]) , Desacyl ghrelin was 2.08+0.20 (Log [desacyl ghrelin fmol/mL]), and no significant change was observed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients complicated with serious diseases such as cancer, hematological disorders, and liver cirrhosis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in blood ghrelin and leptin levels between hemodialysis patients complicated with or without sarcopenia
- Secondary Outcome Measures
Name Time Method Difference in dietary intake and appetite between hemodialysis patients complicated with or without sarcopenia